glp 1 resistance Anti-Inflammatory and Anti-Oxidative Effects of GLP1-RAs and SGLT2i: The Guiding Star Towards Cardiovascular Protection in Type 2 Diabetes Adipose Tissue: A Novel Target
Description
Mehta LS, Velarde GP, Lewey J, Sharma G, Bond RM, Navas-Acien A, et al
The efficacy and safety of tirzepatide in patients with diabetes and/or obesity: systematic review and meta-analysis of randomized clinical trials
In this study, 4076 patients living with T2DM and either a history of CVD (90%) or kidney disease and at least one other cardiovascular risk factor were randomized to receive once-weekly 4 mg or 6 mg efpeglenatide injection or placebo (median follow-up 1.81 years)
Lancet 39221802193
